510(k) Report

510(k) · Cleared

Cleared

Phamatech Quickscreen Benzodiazepines Test, Models 9025, 9026, 9027T, 9153T and 9195X

K043167510(k) SpecialCleared Dec 29, 200443-day reviewClass II21 CFR 862.3170

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Phamatech, Inc. · JXM Enzyme Immunoassay, Benzodiazepine

Cleared on Dec 29, 2004 after a 43-day review. The FDA summary names its predicate without a number.

Decided
Dec 29, 2004
Review
43 days
Class
Class II
Product code
JXM
Recalls
None
Predicates
0

The FDA summary names its predicate without a number.

FIG. 1 — Lineage of K043167Source: FDA 510(k) database · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in JXM? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new JXM device

  1. #1 K243498 Alinity c Benzodiazepines Reagent Kitscore 8.8 · 2 generations · no Class I recall
  2. #2 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*—ABMC RapidOne BZD test
Named without a submission number
—

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

How does its category compare?

All JXM devices

JXM Enzyme Immunoassay, Benzodiazepine: FDA decisions, review times, recalls and adverse event reports over 20 years.

FDA decisions per year · JXM

1in 2024

2010: 12011: 12012: 12015: 22016: 22017: 22018: 12019: 12022: 12024: 1
2007high 2 (2015) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · JXM

Too few JXM 510(k)s in any year since 2007 to give a median.

Recalls per year · JXM

79in 2015

2015: 79
2007high 79 (2015) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · JXM

6in 2025

2008: 32009: 12010: 32011: 32012: 12013: 32014: 32015: 52016: 22017: 42018: 42019: 32021: 12023: 52024: 62025: 6
2007high 6 (2024) · low 0 (2007)2025

MAUDE reports naming product code JXM, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—03
20090—01
20101—03
20111—03
20121—01
20130—03
20140—03
20152—795
20162—02
20172—04
20181—04
20191—03
20200—00
20210—01
20221—00
20230—05
20241—06
20250—06
20260—0—

What is it indicated for?

The QuickScreen Benzodiazepines Test is an in-vitro diagnostic screen that provides a preliminary result for the detection/presence of benzodiazepines in urine. It is intended for professional use only. An invitro diagnostic test for the qualitative detection of amphetamine, cocaine, methamphetamine, opiates, PCP, benzodiazepines, barbiturates, methadone and THC in urine. Measurements obtained by this device are used in the diagnosis and treatment of…

Read the full statement (114 words)

The QuickScreen Benzodiazepines Test is an in-vitro diagnostic screen that provides a preliminary result for the detection/presence of benzodiazepines in urine. It is intended for professional use only.

An invitro diagnostic test for the qualitative detection of amphetamine, cocaine, methamphetamine, opiates, PCP, benzodiazepines, barbiturates, methadone and THC in urine. Measurements obtained by this device are used in the diagnosis and treatment of drug abuse. It is intended for professional use only.

An invitro diagnostic test for the qualitative detection of amphetamine, cocaine, methamphetamine, opiates, PCP, benzodiazepines, barbiturates, methadone and THC in urine. Measurements obtained by this device are used in the diagnosis and treatment of drug abuse. It is intended for professional use only.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K043167: Phamatech Quickscreen Benzodiazepines Test, Models 9025, 9026, 9027T, 9153T and 9195X.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K043167

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Page last updated Nov 3, 2026